Puma Biotechnology (PBYI) Change in Accured Expenses (2011 - 2026)

Puma Biotechnology has reported Change in Accured Expenses for 16 years, with the latest figure at -$11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 18.34% year-over-year to -$11.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (up 206.0% YoY), and the FY2025 full-year result was $13.2 million, up 183.13% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$11.7 million, down from $12.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $20.7 million in Q4 2022, with the low at -$30.9 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$3.2 million across 5 years, with a median of -$1.6 million in 2023.
• The largest YoY upside for Change in Accured Expenses was 1283.49% in 2022 against a maximum downside of 371.28% in 2022.
• Puma Biotechnology's Change in Accured Expenses stood at $20.7 million in 2022, then tumbled by 45.26% to $11.3 million in 2023, then slumped by 221.48% to -$13.8 million in 2024, then soared by 193.54% to $12.9 million in 2025, then sank by 190.83% to -$11.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$11.7 million (Q1 2026), $12.9 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.